– With more than 35 years of leadership experience, Ebbers to oversee
development of Nano-Pulse Electro-Signaling technology for application
in dermatologic conditions –
BURLINGAME, Calif.--(BUSINESS WIRE)--Aug. 24, 2016--
Pulse Biosciences, Inc., (NASDAQ:PLSE), a medical technology company
developing a proprietary therapeutic treatment platform based on
Nano-Pulse Electro-Signaling, today announced that it has appointed
Edward Ebbers, an experienced medical technology executive, as Vice
President and General Manager of its dermatology products.
Ebbers brings more than 35 years of senior leadership and general
management experience with major dermatology, pharmaceutical and device
brands including Zeltiq Aesthetics, Thermage, Penederm Dermatologics,
and most recently as Chief Commercial Officer and Vice President of
Marketing at Capnia. In these roles, he led worldwide product
development, marketing and sales.
“We are pleased to have Ed join our team and lead Pulse Biosciences’
efforts in dermatology. As we ready our PulseTx™ platform for pilot
clinical studies and a planned 510(k) submission, Ed is uniquely
qualified to assemble a team of key opinion leaders to guide and execute
pilot studies and identify clinical applications for entry into the
dermatology market,” said Darrin Uecker, Pulse Biosciences’ President
and Chief Executive Officer. “Our ability to attract an executive of
Ed’s caliber and track record in dermatology is a validation of our
platform’s potential in this market.”
“I am encouraged by the extensive scientific body of evidence
demonstrating the unique potential of the Pulse Biosciences’ platform to
stimulate cell behavior in various tissue types and skin conditions,”
said Mr. Ebbers. “Our clinical studies and product development efforts
will build on this foundation to expand advanced treatment options for
dermatologists and their patients.”
About Pulse Biosciences
Pulse Biosciences (NASDAQ:PLSE) is a medical technology company
developing a therapeutic tissue treatment platform based on Nano-Pulse
Electro-Signaling, a proprietary bioelectronics cell signaling
technology. Published pre-clinical studies have shown that a single,
brief exposure of Nano-Pulse Electro-Signaling to target tissue
initiates a cascade of events within cells and in the surrounding
microenvironment that results in apoptosis (cell death) and the priming
of a durable adaptive immune response. Pulse Biosciences is pursuing a
variety of applications for its technology that exploits the
technology’s unique biologic effect in immuno-oncology, dermatology,
aesthetics, and veterinary medicine. Clinical studies are being planned
using the first commercial system designed to support a broad array of
electrodes for use in superficial, minimally-invasive, and open surgical
procedures. More information is available at www.pulsebiosciences.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160824006115/en/
Source: Pulse Biosciences, Inc.
Investors:
Pulse Biosciences, Inc.
Darrin Uecker, 650-376-0042
President
and Chief Executive Officer
IR@pulsebiosciences.com
or
Media:
Sam
Brown, Inc.
Hannah Hurdle, 818-456-4099
hannahhurdle@sambrown.com
